


**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 
- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Raw Sequence Listing Error Summary




ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/169,048

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 Misaligned Amino Acid The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
Numbering between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.
- 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) 4, 6, 8, 10, 12. Normally, PatentIn would automatically generate this section from the
14, 18, 20, 22 previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
(maybe more) to the subsequent amino acid sequence.
- 8 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:
 (1) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
 (x1) SEQUENCE DESCRIPTION:SEQ ID NO:X:
 This sequence is intentionally skipped
- Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
(NEW RULES) <210> sequence id number
 <400> sequence id number
 000
- 10 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 Use of <213>Organism Sequence(s) are missing this mandatory field or its response.
(NEW RULES)
- 12 Use of <220>Feature Sequence(s) are missing the <220>Feature and associated headings.
(NEW RULES) Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
 Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.



W SEQUENCE LISTING

PATENT APPLICATION US/09/169,048

DATE: 01/18/2000

TIME: 14:24:46

Input Set: I169048.RAW

This raw listing contains the General Information
Section and up to first 5 pag s.

Does Not Comply
Corrected Diskette Needed

pp15

1 <110> APPLICANT: Huse, William D.
2 Freedman, Michael H.
3 <120> TITLE OF INVENTION: Method for Identifying Optimal Binding Ligands to a
4 Receptor
5 <130> FILE REFERENCE: P-IX 3280
6 <140> CURRENT APPLICATION NUMBER: US/09/169,048
7 <141> CURRENT FILING DATE: 1998-10-08
8 <150> EARLIER APPLICATION NUMBER: 60/112,011
9 <151> EARLIER FILING DATE: 1997-10-09
10 <160> NUMBER OF SEQ ID NOS: 28
11 <170> SOFTWARE: PatentIn Ver. 2.0
12 <210> SEQ ID NO 1
13 <211> LENGTH: 24
14 <212> TYPE: DNA
15 <213> ORGANISM: Mus musculus
16 <220> FEATURE:
17 <221> NAME/KEY: CDS
18 <222> LOCATION: (1)..(24)
19 <400> SEQUENCE: 1
20 agc tca agt gta agt ttc atg aac 24
21 Ser Ser Ser Val Ser Phe Met Asn
22 1 5
23 <210> SEQ ID NO 2
24 <211> LENGTH: 8
25 <212> TYPE: PRT
26 <213> ORGANISM: Mus musculus
27 <400> SEQUENCE: 2
28 Ser Ser Ser Val Ser Phe Met Asn
29 1 5
30 <210> SEQ ID NO 3
31 <211> LENGTH: 24
32 <212> TYPE: DNA
33 <213> ORGANISM: Artificial Sequence
34 <220> FEATURE:
35 <221> NAME/KEY: CDS
36 <222> LOCATION: (1)..(24)
37 <220> FEATURE:
38 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
39 construct
40 <400> SEQUENCE: 3
41 agc tca agt gta agg ttc atg aac 24
42 Ser Ser Ser Val Arg Phe Met Asn
43 1 5
44 <210> SEQ ID NO 4

PAGE: 2

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/169,048

DATE: 01/18/2000
TIME: 14:24:46

Input Set: I169048.RAW

45 <211> LENGTH: 8
 46 <212> TYPE: PRT
 47 <213> ORGANISM: Artificial Sequence
 48 <400> SEQUENCE: 4
 49 Ser Ser Ser Val Arg Phe Met Asn
 50 1 5
 51 <210> SEQ ID NO 5
 52 <211> LENGTH: 24
 53 <212> TYPE: DNA
 54 <213> ORGANISM: Artificial Sequence
 55 <220> FEATURE:
 56 <221> NAME/KEY: CDS
 57 <222> LOCATION: (1)..(24)
 58 <220> FEATURE:
 59 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
 60 construct
 61 <400> SEQUENCE: 5
 62 agc gag agt gta aat ctt atg aac 24
 63 Ser Glu Ser Val Asn Leu Met Asn
 64 1 5
 65 <210> SEQ ID NO 6
 66 <211> LENGTH: 8
 67 <212> TYPE: PRT
 68 <213> ORGANISM: Artificial Sequence
 69 <400> SEQUENCE: 6
 70 Ser Glu Ser Val Asn Leu Met Asn
 71 1 5
 72 <210> SEQ ID NO 7
 73 <211> LENGTH: 24
 74 <212> TYPE: DNA
 75 <213> ORGANISM: Artificial Sequence
 76 <220> FEATURE:
 77 <221> NAME/KEY: CDS
 78 <222> LOCATION: (1)..(24)
 79 <220> FEATURE:
 80 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
 81 construct
 82 <400> SEQUENCE: 7
 83 agc tca agt gtt aat ttc atg aac 24
 84 Ser Ser Ser Val Asn Phe Met Asn
 85 1 5
 86 <210> SEQ ID NO 8
 87 <211> LENGTH: 8
 88 <212> TYPE: PRT
 89 <213> ORGANISM: Artificial Sequence
 90 <400> SEQUENCE: 8
 91 Ser Ser Ser Val Asn Phe Met Asn
 92 1 5
 93 <210> SEQ ID NO 9
 94 <211> LENGTH: 24

Section 7 on Error Summary Sheet

Item 7

Item 7

PAGE: 3

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/169,048DATE: 01/18/2000
TIME: 14:24:46

Input Set: I169048.RAW

95 <212> TYPE: DNA
96 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <221> NAME/KEY: CDS
99 <222> LOCATION: (1)..(24)
100 <220> FEATURE:
101 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
102 construct
103 <400> SEQUENCE: 9
104 agc tca acg gta agt ttc atg aac 24
105 Ser Ser Thr Val Ser Phe Met Asn
106 1 5
107 <210> SEQ ID NO 10
108 <211> LENGTH: 8
109 <212> TYPE: PRT
110 <213> ORGANISM: Artificial Sequence
111 <400> SEQUENCE: 10
112 Ser Ser Thr Val Ser Phe Met Asn
113 1 5
114 <210> SEQ ID NO 11
115 <211> LENGTH: 24
116 <212> TYPE: DNA
117 <213> ORGANISM: Artificial Sequence
118 <220> FEATURE:
119 <221> NAME/KEY: CDS
120 <222> LOCATION: (1)..(24)
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
123 construct
124 <400> SEQUENCE: 11
125 agc tca agt gta gcg tat atg aac 24
126 Ser Ser Ser Val Ala Tyr Met Asn
127 1 5
128 <210> SEQ ID NO 12
129 <211> LENGTH: 8
130 <212> TYPE: PRT
131 <213> ORGANISM: Artificial Sequence
132 <400> SEQUENCE: 12
133 Ser Ser Ser Val Ala Tyr Met Asn
134 1 5
135 <210> SEQ ID NO 13
136 <211> LENGTH: 24
137 <212> TYPE: DNA
138 <213> ORGANISM: Artificial Sequence
139 <220> FEATURE:
140 <221> NAME/KEY: CDS
141 <222> LOCATION: (1)..(24)
142 <220> FEATURE:
143 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
144 construct

PAGE: 4

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/169,048DATE: 01/18/2000
TIME: 14:24:46

Input Set: I169048.RAW

145 <400> SEQUENCE: 13
146 agc cag agt gct aag cat atg aac 24
147 Ser Gln Ser Ala Lys His Met Asn
148 1 5
149 <210> SEQ ID NO 14
150 <211> LENGTH: 8
151 <212> TYPE: PRT
152 <213> ORGANISM: Artificial Sequence
153 <400> SEQUENCE: 14
154 Ser Gln Ser Ala Lys His Met Asn
155 1 5
156 <210> SEQ ID NO 15
157 <211> LENGTH: 24
158 <212> TYPE: DNA
159 <213> ORGANISM: Mus musculus
160 <220> FEATURE:
161 <221> NAME/KEY: CDS
162 <222> LOCATION: (1)..(24).
163 <400> SEQUENCE: 15
164 gcc aca tcc aat ttg gct tct gga 24
165 Ala Thr Ser Asn Leu Ala Ser Gly
166 1 5
167 <210> SEQ ID NO 16
168 <211> LENGTH: 8
169 <212> TYPE: PRT
170 <213> ORGANISM: Mus musculus
171 <400> SEQUENCE: 16
172 Ala Thr Ser Asn Leu Ala Ser Gly
173 1 5
174 <210> SEQ ID NO 17
175 <211> LENGTH: 24
176 <212> TYPE: DNA
177 <213> ORGANISM: Artificial Sequence
178 <220> FEATURE:
179 <221> NAME/KEY: CDS
180 <222> LOCATION: (1)..(24)
181 <220> FEATURE:
182 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
183 construct
184 <400> SEQUENCE: 17
185 gcc aca gag aag ttg gct tct gga 24
186 Ala Thr Glu Lys Leu Ala Ser Gly
187 1 5
188 <210> SEQ ID NO 18
189 <211> LENGTH: 8
190 <212> TYPE: PRT
191 <213> ORGANISM: Artificial Sequence
192 <400> SEQUENCE: 18
193 Ala Thr Glu Lys Leu Ala Ser Gly
194 1 5

PAGE: 5

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/169,048DATE: 01/18/2000
TIME: 14:24:46

Input Set: I169048.RAW

195 <210> SEQ ID NO 19
196 <211> LENGTH: 24
197 <212> TYPE: DNA
198 <213> ORGANISM: Artificial Sequence
199 <220> FEATURE:
200 <221> NAME/KEY: CDS
201 <222> LOCATION: (1)..(24)
202 <220> FEATURE:
203 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
204 construct
205 <400> SEQUENCE: 19
206 gcc aca gtt aat ttg gct tct gga 24
207 Ala Thr Val Asn Leu Ala Ser Gly
208 1 5
209 <210> SEQ ID NO 20
210 <211> LENGTH: 8
211 <212> TYPE: PRT
212 <213> ORGANISM: Artificial Sequence
213 <400> SEQUENCE: 20
214 Ala Thr Val Asn Leu Ala Ser Gly
215 1 5
216 <210> SEQ ID NO 21
217 <211> LENGTH: 24
218 <212> TYPE: DNA
219 <213> ORGANISM: Artificial Sequence
220 <220> FEATURE:
221 <221> NAME/KEY: CDS
222 <222> LOCATION: (1)..(24)
223 <220> FEATURE:
224 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
225 construct
226 <400> SEQUENCE: 21
227 gcc aca gtg aat ttg gct tct gga 24
228 Ala Thr Val Asn Leu Ala Ser Gly
229 1 5
230 <210> SEQ ID NO 22
231 <211> LENGTH: 8
232 <212> TYPE: PRT
233 <213> ORGANISM: Artificial Sequence
234 <400> SEQUENCE: 22
235 Ala Thr Val Asn Leu Ala Ser Gly
236 1 5
237 <210> SEQ ID NO 23
238 <211> LENGTH: 24
239 <212> TYPE: DNA
240 <213> ORGANISM: Artificial Sequence
241 <220> FEATURE:
242 <221> NAME/KEY: CDS
243 <222> LOCATION: (1)..(24)
244 <220> FEATURE:

PAGE: 6

VERIFICATION SUMMARY
PATENT APPLICATION US/09/169,048

DATE: 01/18/2000
TIME: 14:24:46

Input Set: I169048.RAW

Line ? Error/Warning

Original Text



PATENT
Our Docket: P-IX 3280

4/15/00
11/B
Hanna
4/18/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Huse and Freedman)
Serial No.: 09/169,048)
Filed: October 8, 1998)
For: METHOD FOR IDENTIFYING)
OPTIMAL BINDING LIGANDS)
TO A RECEPTOR)

Group Art Unit: 1627
Examiner: M. Garcia

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE, Assistant Commissioner for Patents, Washington, D.C. 20231, on March 28, 2000.

By Deborah L. Cadena
Deborah L. Cadena, Reg. No. 44,048

March 28, 2000

Date of Signature

BOX SEQUENCE

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT UNDER 37 C.F.R. § 1.825(a) and (b)

I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825 (a), included in the substitute computer readable form and paper copy of the Sequence Listing are supported in the application, as filed on October 8, 1998. I hereby state that the substitute paper copy of the Sequence Listing does not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR § 1.825 (b), is the same as the amended Sequence Listing.

Respectfully submitted,

March 28, 2000

Date

Deborah L. Cadena

Deborah L. Cadena

Registration No. 44,048

Telephone: (858) 535-9001

Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122
USPTO CUSTOMER NO. 23601

Inventors: Huse and Freedman
Serial No.: 09/169,048
Filed: October 8, 1998
Page 2

Please charge any additional fees or credit any
overpayment to Deposit Account No. 03-0370. A duplicate copy
of this sheet is enclosed.

Respectfully submitted,


Date: March 28, 2000



Deborah L. Cadena
Registration No. 44,048
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122
USPTO CUSTOMER NO. 23601

APR 11 2000



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/169,048	10/8/98	Huse, et al	P-IX-3280

EXAMINER	
Maurie E. Garcia, Ph. D.	
ART UNIT	PAPER NUMBER
1627	

DATE MAILED:

Notice to Comply

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner **Maurie E. Garcia, Ph. D.**, Art Unit **1627**, whose telephone number is **(703) 308-0065**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.